标准化纤维蛋白溶解治疗对肺炎旁积液的疗效
该研究在儿童肺炎旁积液患者中引入全院临床路径,标准化介入放射科医师的纤溶药物给药方案(根据胸腔超声分级给予组织型纤溶酶原激活剂1-2 mg每日两次),并前瞻性收集2017年5月至2020年2月的介入治疗数据,与2013年1月至2017年4月的历史对照比较。结果显示,路径实施后介入转诊增加,患者合并症更多、儿科重症监护病房入住更多,每日平均剂量从1.5 mg增至1.9 mg,每日两次给药天数从38%增至79%,中位胸腔治疗天数从3.5天降至2.5天,无患者需要外科干预。
要点
- 标准化纤溶给药后,每日两次给药天数从38%增至79%,中位胸腔治疗天数从3.5天降至2.5天。
- 路径实施后介入转诊增加,患者合并症更多、儿科重症监护病房入住更多,但无患者需要外科干预。
- 胸腔超声分级与培养阳性、需胸部CT或二次介入操作及胸腔治疗天数相关。
核心结论
- 介入放射科医师标准化改善了肺炎旁积液纤溶治疗的临床路径,尽管患者复杂度更高,胸腔治疗持续时间缩短,无需要外科引流的胸管失败。
研究设计与样本
- 研究为临床路径实施前后的前瞻性数据与历史对照比较,路径实施后前瞻性收集2017年5月至2020年2月介入治疗数据,历史对照为2013年1月至2017年4月介入治疗数据;共63名儿童和年轻成人接受路径后治疗;参考标准为胸腔超声分级。
诊断标准与关键数值
- 根据胸腔超声分级给予组织型纤溶酶原激活剂1-2 mg每日两次。
- 路径实施后每日平均剂量从1.5 mg增至1.9 mg(P < 0.001),每日两次给药天数从38%增至79%(P < 0.001),中位胸腔治疗天数从3.5天降至2.5天(P = 0.001)。
- 介入转诊增加(P = 0.02),合并症更多(P = 0.005),儿科重症监护病房患者更多(P = 0.05)。
- 性别、年龄、体重、超声分级、需二次介入操作或住院时间无统计学差异。
- 胸腔超声分级与培养阳性更多、需胸部CT或二次介入操作及胸腔治疗天数相关。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: While chest tube placement with pleural fibrinolytic medication is the established treatment of pediatric empyema, treatment failure is reported in up to 20% of these children.
OBJECTIVE: Standardizing fibrinolytic administration among interventional radiology (IR) physicians to improve patient outcomes in pediatric parapneumonic effusion.
MATERIALS AND METHODS: We introduced a hospital-wide clinical pathway for parapneumonic effusion (1-2 mg tissue plasminogen activator [tPA] twice daily based on pleural US grade); we then collected prospective data for IR treatment May 2017 through February 2020. These data included demographics, co-morbidities, pediatric intensive care unit (PICU) admission, pleural US grade, culture results, daily tPA dose average, twice-daily dose days, skipped dose days, pleural therapy days, need for chest CT/a second IR procedure/surgical drainage, and length of stay. We compared the prospective data to historical controls with IR treatment from January 2013 to April 2017.
RESULTS: Sixty-three children and young adults were treated after clinical pathway implementation. IR referrals increased (P = 0.02) and included higher co-morbidities (P = 0.005) and more PICU patients (P = 0.05). Mean doses per day increased from 1.5 to 1.9 (P < 0.001), twice-daily dose days increased from 38% to 79% (P < 0.001) and median pleural therapy days decreased from 3.5 days to 2.5 days (P = 0.001). No IR patients needed surgical intervention. No statistical differences were observed for gender/age/weight, US grade, need for a second IR procedure or length of stay. US grade correlated with greater positive cultures, need for chest CT/second IR procedure, and pleural therapy days.
CONCLUSION: Interventional radiology physician standardization improved on a clinical pathway for fibrinolysis of parapneumonic effusion. Despite higher patient complexity, pleural therapy duration decreased. There were no chest tube failures needing surgical drainage.
引用
- James, Lewis, Moore, et al. Efficacy of standardizing fibrinolytic therapy for parapneumonic effusion. Pediatr Radiol. 2022. PMID: 35451632. doi:10.1007/s00247-022-05365-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。